Presence of Tumour and Higher Levels of LAG3-positive T-cells in the Blood May Be Necessary to Derive Clinical Benefit with Nivolumab Plus Relatlimab Over Nivolumab in Melanoma By Ogkologos - November 11, 2025 264 0 Facebook Twitter Google+ Pinterest WhatsApp Primary results of RELATIVITY-098 and translational evidence from RELATIVITY-098 and RELATIVITY-047 studies Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR How to Get Started With Exercising at Home During Cancer July 7, 2022 Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment... April 27, 2026 EMA Recommends Granting a Marketing Authorisation for Tislelizumab August 4, 2023 Cancer Surgery Unexpectedly Canceled for Mother of Two, Who Says It’s... March 31, 2020 Load more HOT NEWS When Cancer Spreads to Bone, A Single Dose of Radiation Therapy... Scientists Focus on Fusion Proteins in Childhood Cancers FDA Grants Accelerated Approval to Tucatinib with Trastuzumab for Colorectal Cancer Doctor Wipes Away The Debt Of 200 Cancer Patients
